Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Early data with the RIPTAC HLD-0915 look competitive.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.